loading
Lucid Diagnostics Inc stock is traded at $1.10, with a volume of 663.15K. It is up +4.76% in the last 24 hours and down -1.79% over the past month. Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.05
Open:
$1.06
24h Volume:
663.15K
Relative Volume:
0.60
Market Cap:
$119.33M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0185
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
+7.84%
1M Performance:
-1.79%
6M Performance:
-24.66%
1Y Performance:
+29.87%
1-Day Range:
Value
$1.035
$1.10
1-Week Range:
Value
$0.98
$1.10
52-Week Range:
Value
$0.73
$1.80

Lucid Diagnostics Inc Stock (LUCD) Company Profile

Name
Name
Lucid Diagnostics Inc
Name
Phone
212 949 4319
Name
Address
360 MADISON AVENUE, NEW YORK
Name
Employee
70
Name
Twitter
Name
Next Earnings Date
2025-03-24
Name
Latest SEC Filings
Name
LUCD's Discussions on Twitter

Compare LUCD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
LUCD
Lucid Diagnostics Inc
1.10 103.93M 4.35M -45.53M -44.79M -1.08
Medical Devices icon
ABT
Abbott Laboratories
132.59 226.73B 43.11B 13.94B 6.78B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
106.17 152.69B 18.49B 2.50B 3.49B 1.68
Medical Devices icon
SYK
Stryker Corp
394.22 145.89B 23.82B 2.92B 4.02B 7.55
Medical Devices icon
MDT
Medtronic Plc
92.71 118.91B 33.54B 4.69B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
81.83 45.97B 5.69B 1.41B 577.90M 6.95

Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-27-21 Initiated Ascendiant Capital Markets Buy
Nov-08-21 Initiated BTIG Research Buy
Nov-08-21 Initiated Cantor Fitzgerald Overweight
Nov-08-21 Initiated Needham Buy

Lucid Diagnostics Inc Stock (LUCD) Latest News

pulisher
Aug 19, 2025

Lucid Diagnostics Reports Q2 2025 Financial Results - MSN

Aug 19, 2025
pulisher
Aug 19, 2025

Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG - MSN

Aug 19, 2025
pulisher
Aug 19, 2025

Cantor Fitzgerald reiterates Overweight rating on Lucid Diagnostics stock - Investing.com

Aug 19, 2025
pulisher
Aug 19, 2025

Cantor Fitzgerald reiterates Overweight rating on Lucid Diagnostics stock By Investing.com - Investing.com UK

Aug 19, 2025
pulisher
Aug 18, 2025

Lucid Diagnostics Q2 2025 Earnings Miss: A Deep Dive Into the Market Impact and Investor Strategy - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Lucid Diagnostics Posts Earnings Miss; Market Reaction and Investor Caution Rise - AInvest

Aug 17, 2025
pulisher
Aug 16, 2025

Lucid Diagnostics Q2 Earnings Misses, Drives Negative Market Sentiment - AInvest

Aug 16, 2025
pulisher
Aug 15, 2025

PAVmed Reports Q2 2025 Financial Results: $13.3M Net Loss, $1.2M in Lucid Diagnostics Revenue - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Lucid Diagnostics Q2 2025 Earnings Call Transcript - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Lucid Diagnostics shares rise 2.04% intraday after securing capital to extend runway past key reimbursement milestones. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Quant Funds Rotate Into Lucid Diagnostics Inc. StockMarket Weekly Review & Intraday High Probability Alerts - newsyoung.net

Aug 15, 2025
pulisher
Aug 15, 2025

PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth - Investing.com

Aug 15, 2025
pulisher
Aug 15, 2025

Lucid Diagnostics Q2 2025 Earnings: Revenue Grows, Net Loss Widens - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Support Buy Rating - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Lucid Diagnostics Misses Earnings Again: Mixed Market Impact Amid Sector Resilience - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics Advances Towards Medicare Coverage - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Justify Buy Rating - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 14, 2025
pulisher
Aug 14, 2025

PAVmed Reports Q2 2025 Financial Results, Lucid Diagnostics Recognizes $1.2M in Revenue and Processes 2,756 Tests - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace

Aug 14, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics Q2 2025 Earnings: Revenue Up, Loss Widens Amid Ongoing Expenses - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Lucid Diagnostics Reports Q2 2025 Earnings - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Maintains Buy Rating Amid Potential Medicare Coverage Expansion and Financial Stability - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Reports Q2 Earnings, Revenue Below Consensus, CEO Optimistic on Medicare Coverage - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics (LUCD): Navigating Medicare Coverage Milestones and Commercial Expansion to Unlock Long-Term Value - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Q2 2025: Conflicting Insights on Medicare Coverage, Patient Strategy, and Claims Process - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics at Canaccord Conference: Medicare Coverage in Focus By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics: Needham Reiterates Buy Rating, Raises PT to $3 - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics: Buy Rating Affirmed Amid Potential Medicare Coverage Expansion and Financial Resilience - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics reports Q2 non-GAAP EPS (10c), consensus (10c) - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Earnings call transcript: Lucid Diagnostics Q2 2025 revenue up, stock dips - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Q2 2025 Earnings: Revenue Exceeds Expectations, EPS Beats Estimates, Cash Position Strengthens - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics reports $1.2mln revenue, $30mln cash, extends runway past reimbursement milestones. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics earnings beat, revenue was in line with estimates By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Inc Q2 loss per share $0.08 - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics Q2 revenue up 1000% YoY to $1.2mln, cash runway extended. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

LUCD Reports Results - Nasdaq

Aug 13, 2025
pulisher
Aug 13, 2025

Lucid Diagnostics 2025 Q2 Earnings Losses Narrow as Net Income Improves 59.7% - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Lucid Diagnostics Inc. SEC 10-Q Report - TradingView

Aug 12, 2025
pulisher
Aug 12, 2025

PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

What To Expect From Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings - Yahoo Finance

Aug 12, 2025
pulisher
Aug 10, 2025

Lucid Diagnostics LUCD 2025Q2 Earnings Preview Downside Anticipated on Underwhelming Market Performance - AInvest

Aug 10, 2025
pulisher
Aug 09, 2025

Why Lucid Diagnostics Inc. stock attracts strong analyst attentionDaily Growth Stock Pick Reports Show Bullish Signals - metal.it

Aug 09, 2025
pulisher
Aug 06, 2025

Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress

Aug 06, 2025

Lucid Diagnostics Inc Stock (LUCD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lucid Diagnostics Inc Stock (LUCD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Matheis Dennis
Director
May 20 '25
Buy
1.29
187,098
242,292
187,098
Matheis Dennis
Director
May 21 '25
Buy
1.32
129,684
171,520
316,782
Matheis Dennis
Director
May 22 '25
Buy
1.32
33,218
43,795
350,000
$330.77
price up icon 0.89%
medical_devices STE
$251.87
price up icon 1.77%
medical_devices PHG
$28.34
price up icon 3.28%
$82.26
price up icon 2.03%
$75.22
price up icon 2.83%
medical_devices EW
$81.83
price up icon 0.83%
Cap:     |  Volume (24h):